AZD1236, currently in Phase 2 trials, has shown an 80% preservation in nerve function following spinal cord injury.
AZD1236, currently in Phase 2 trials, has shown an 80% preservation in nerve function following spinal cord injury.
A new seizure drug has been approved, and a nerve growth drug advances in clinical trials.
